Cutaneous Leishmaniasis (CL) is among the neglected endemic diseases of America, Africa, India, southwest Asia and the Mediterranean (
1). Nowadays, 12 million people in the world suffer from this disease. The annual incidence of leishmaniasis in the world is estimated at 1 to 1.5 million. Iran is one of the ten countries in which cutaneous leishmaniasis has constantly been reported to have a high prevalence (
2). About 20,000 cases of leishmaniasis are reported annually in this country, but the actual prevalence of the disease appears to be four to five times higher. The prevalence of infection has been reported as 1.8% to 37.9% in different provinces of Iran (
3). Cutaneous leishmaniasis has two forms, including Anthroponotic Cutaneous Leishmaniasis (ACL), which is caused by
Leishmania tropica (
L. tropica), and Zoonotic Cutaneous Leishmaniasis (ZCL), which is caused by
Leishmania major (
L. major).
L. tropica is transmitted to human beings by the bite of infected female
Phlebotomus sergenti.
Phlebotomus papatasi, the most prevalent species of the
Phlebotomus genus, is the only known vector of
L. major (
4). The identification and characterization of different species of leishmaniasis is one of the main factors involved in the prevention and control of this disease. Determining the dominant strain in each region has applications in the pharmaceutical industry, vaccination and the production of antigens for disease diagnosis (
5).